A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.
about
Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitusAntiplatelet agents and anticoagulants for hypertensionAntiplatelet agents and anticoagulants for hypertensionAspirin and extended-release dipyridamole versus clopidogrel for recurrent strokeResults of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?Is clopidogrel superior to aspirin in secondary prevention of vascular disease?Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-AnalysisAntiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysisClopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromesAntiplatelet treatment for secondary prevention of acute ischemic stroke and transient ischemic attacks: mechanisms, choices and possible emerging patterns of useClinical use of new antithrombotic therapies for medical management of acute coronary syndromesAntiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndromeRegular or "super-aspirins"? A review of thienopyridines or aspirin to prevent strokeSystematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular diseaseAntiplatelet agents for secondary prevention of ischemic strokeIs acetylsalicylic acid plus dipyridamole superior to ASA alone for secondary prevention of stroke?Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agentsEconomic evaluation of triflusal and aspirin in the treatment of acute myocardial infarctionIschemic stroke prevention: an update on antiplatelet therapyThe safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart diseaseAntithrombotic therapy in hypertension: a Cochrane Systematic reviewRecent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problemsAntiplatelet therapy in populations at high risk of atherothrombosisClopidogrel: an updated and comprehensive reviewThe PRoFESS trial: future impact on secondary stroke preventionSecondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?Drug points: Ticlopidine associated with acute arthritisDifferences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella reviewCollaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' CollaborationHuman complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysisCilostazol: treatment of intermittent claudication.[Ticlopidine-associated thrombotic thrombocytopenic purpura (Morbus Moschcowitz)].Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases.Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome associated with clopidogrel: report of two new cases.Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon.Ticlopidine and fatal aplastic anemia in an elderly woman.Fatal neutropenia and thrombocytopenia associated with ticlopidine.
P2860
Q24203035-6BD63CD4-84A9-46AE-A055-AB718D14A05BQ24234617-27F06415-C78B-4CC7-8D48-EB86D65240B0Q24246637-3A01A129-5E9E-4EC0-B82D-F75B9C692736Q24646522-5101BB3B-407D-4C87-A44E-9D4780260D23Q24792611-B6B5B805-A7C9-439C-BC8E-F0CE6297CBBAQ24792794-F52DFDED-6F31-4474-9CD8-90A64699B6B7Q26797510-561166DE-A340-40FA-8405-58BF03207E0EQ28076042-4F87D07D-4060-4B2A-B65E-BB881CAB8E1FQ28167896-77AAF97B-6AF6-46ED-96E5-05EFC4FC3425Q28167899-969A85BD-A93B-420C-9C6F-2D6F336228CFQ28177271-BF2A3482-1F1A-44CF-B128-60FE58E42470Q28182136-09F3D307-48EA-4C8E-B06A-C62903DA2AC0Q28183391-9FE18DE2-84AF-4AC1-97F3-163A48E7D1BEQ28185314-3682DA6B-6359-46D4-AA6B-600C53D44A72Q28190669-CEF11C8D-9501-4FF4-ADF0-C6B8D6838185Q28191988-69064241-2026-4683-BFDA-DF5E52A15CCFQ28192470-71A3E3C5-5ACE-4E2F-A75C-08159546774BQ28192692-7801A48C-6155-4272-871A-27D696BD7F08Q28193224-3593E52F-31B5-4A26-8AAF-6DA486A38520Q28200757-FDFA633C-239F-4B6A-8081-02313C44D149Q28213879-0A15D8AB-0242-4C54-91D2-7356B57C254EQ28218351-6F78C013-297C-4A5D-B6A0-617A9CCF7B1CQ28218702-E11447BE-FBEB-4AF9-AC54-2965E0BBDFAEQ28219411-DB582750-E789-4565-82FB-3D87550C5BC3Q28221589-1712953E-5FDB-48B6-89A3-EE9482DEB88DQ28221595-44DB5010-C188-4399-BC66-76A73B0F2DF2Q28344509-ED052647-3202-404C-A663-462F6C36BE67Q28474985-63316F89-FB1C-4FA4-B491-6CA7331D7C75Q29619529-7A217E6C-8FD2-426E-B963-A077F01B8EB6Q30444430-CCCB74A1-E71F-4AE7-8CCC-7CF1DBDA3924Q31989672-CC0464F2-47E1-4C3C-ACA9-2A4B1AD0B33DQ33331425-4EA33A0B-23FF-4A3A-AF6A-F1BF5C254B87Q33335969-E868EFD1-F5A9-464D-AE46-5D97B4F266F2Q33344214-AF563644-73C6-4287-8C9A-B906D7CB02C8Q33362149-F020F005-668B-40B7-B328-73056BBBC73DQ33383006-5F3F7FF6-1DE4-4150-948E-4F7CB986F87AQ33404125-1A8CB5B5-A922-4534-9970-8C362EABF2E9Q33407224-C88CAC24-DEE0-4189-BB08-A4FBADF07867Q33490299-6B5A54DC-B109-4CC1-9B97-AC1B94D39BE1Q33490373-A98F793F-5ED6-4EE2-8146-37E974331962
P2860
A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.
description
1989 nî lūn-bûn
@nan
1989 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
A randomized trial comparing t ...... ne Aspirin Stroke Study Group.
@ast
A randomized trial comparing t ...... ne Aspirin Stroke Study Group.
@en
A randomized trial comparing t ...... ne Aspirin Stroke Study Group.
@nl
type
label
A randomized trial comparing t ...... ne Aspirin Stroke Study Group.
@ast
A randomized trial comparing t ...... ne Aspirin Stroke Study Group.
@en
A randomized trial comparing t ...... ne Aspirin Stroke Study Group.
@nl
prefLabel
A randomized trial comparing t ...... ne Aspirin Stroke Study Group.
@ast
A randomized trial comparing t ...... ne Aspirin Stroke Study Group.
@en
A randomized trial comparing t ...... ne Aspirin Stroke Study Group.
@nl
P2093
P1476
A randomized trial comparing t ...... ne Aspirin Stroke Study Group.
@en
P2093
Adams HP Jr
Anderson S
Pryse-Phillips W
P304
P356
10.1056/NEJM198908243210804
P407
P577
1989-08-01T00:00:00Z